These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 28126272)
21. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309 [TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
23. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. George DJ; Halabi S; Heath EI; Sartor AO; Sonpavde GP; Das D; Bitting RL; Berry W; Healy P; Anand M; Winters C; Riggan C; Kephart J; Wilder R; Shobe K; Rasmussen J; Milowsky MI; Fleming MT; Bearden J; Goodman M; Zhang T; Harrison MR; McNamara M; Zhang D; LaCroix BL; Kittles RA; Patierno BM; Sibley AB; Patierno SR; Owzar K; Hyslop T; Freedman JA; Armstrong AJ Cancer; 2021 Aug; 127(16):2954-2965. PubMed ID: 33951180 [TBL] [Abstract][Full Text] [Related]
24. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263 [TBL] [Abstract][Full Text] [Related]
25. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004 [TBL] [Abstract][Full Text] [Related]
26. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813 [TBL] [Abstract][Full Text] [Related]
27. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621 [TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. Lim J; Amantakul A; Shariff N; Lojanapiwat B; Alip A; Ong TA; Thevarajah S; Ahmayuddin F; Mathew A; Sriplakich S; Vuthiwong J; Chong FLT; Saad M Cancer Med; 2020 Jul; 9(13):4613-4621. PubMed ID: 32374087 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study. Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Boccasile S; Ditonno P; Chiodini P; Verze P; Mirone V; Schips L BMC Cancer; 2017 Nov; 17(1):753. PubMed ID: 29126389 [TBL] [Abstract][Full Text] [Related]
30. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821 [TBL] [Abstract][Full Text] [Related]
31. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187 [TBL] [Abstract][Full Text] [Related]
32. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527 [TBL] [Abstract][Full Text] [Related]
33. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Di Lorenzo G; Sonpavde G; Pond G; Lucarelli G; Rossetti S; Facchini G; Scagliarini S; Cartenì G; Federico P; Daniele B; Morelli F; Bellelli T; Ferro M; De Placido S; Buonerba C Eur Urol Focus; 2018 Dec; 4(6):874-879. PubMed ID: 28753882 [TBL] [Abstract][Full Text] [Related]
34. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919 [TBL] [Abstract][Full Text] [Related]
35. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983 [TBL] [Abstract][Full Text] [Related]
36. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. Tsao CK; Sfakianos J; Liaw B; Gimpel-Tetra K; Kemeny M; Bulone L; Shahin M; Oh WK; Galsky MD Oncologist; 2016 Dec; 21(12):1414-e9. PubMed ID: 27742908 [TBL] [Abstract][Full Text] [Related]
37. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845 [TBL] [Abstract][Full Text] [Related]
38. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060 [TBL] [Abstract][Full Text] [Related]
39. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372 [TBL] [Abstract][Full Text] [Related]
40. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]